# PathMap Report Trace Context: #00000045
Hypothesis: Sporadic ALS and C9orf72 affected ALS are two different pathologies and the mixing of test groups and datasets has produced confounding results.
Author: Joshua Dungan (PathMap.org)
License: 'THE GLOBAL HUMANITARIAN PROPRIETARY LICENSE (VERSION 1.0.1)' https://pathmap.org/license.pdf
Full provenance JSON trace: https://pathmap.org/download.php/?id=45
==================================================

SYSTEM NOTE: The eight-digit ID numbers (e.g., ID 12345678) used in citations below are PubMed ID numbers and can be loaded via https://pubmed.ncbi.nlm.nih.gov/{ID}/ for verification.

==================================================

## Primary Synthesis & Clinical Bottom-Line
Scientific investigation into ALS reveals that it is a clinically and genetically heterogeneous syndrome. While certain pathways, such as nucleocytoplasmic transport and protein aggregation, are shared across both C9orf72-expanded and sporadic cases, specific molecular programs show subtype-dependent divergence. Stratification of patients based on these distinct molecular signatures is essential to overcome the diagnostic and prognostic challenges posed by disease heterogeneity.

## Plausibility Verdicts
- Evaluation 1: Yes, current literature supports the clinical necessity of differentiating C9orf72-ALS and sALS due to distinct molecular trajectories and endotypes.
- Evaluation 2: Yes, sporadic and C9orf72-associated ALS have distinct molecular and inflammatory profiles that make grouping them as a single pathology problematic for precision medicine.

## Novel & Overlooked Insights
- Nucleocytoplasmic transport impairment is a unifying mechanism found in both SOD1-mediated cases and other familial or sporadic forms.
- C9orf72-associated cases are not merely distinct but represent a significant fraction of both familial and sporadic cases, contributing to clinical heterogeneity.
- The hnRNP network shows glia-specific RNA-processing alterations that may differentiate pathological subtypes of FTLD-TDP.
- Immune exclusion in cervical squamous carcinoma, while oncological, provides a translational framework for how spatial organization affects treatment stratification.
- Innate immune activation (e.g., cGAS-STING, NLRP3) is an active driver of ALS/FTD progression rather than a secondary bystander.
- Transcriptomic analysis of monozygotic twins discordant for ALS highlights epigenetic dysregulation and immune system pathways as potential drivers.
- Large-scale genomic surveys identify rare somatic mutations in sporadic cases that may contribute to widespread degeneration.
- VAPB levels in specific neurons correlate with selective vulnerability to disease, with resistant motor neurons exhibiting higher VAPB immunoreactivity.
- C9orf72-associated ALS microglia adopt disease-associated states through mechanisms involving ESCRT-mediated lysosomal repair, a feature less characterized in broader sALS cohorts.
- The APOE ε4 allele is directly associated with widespread, "type 2" TDP-43 pathology in sALS, independent of Alzheimer's-related pathologies, suggesting an additional layer of patient stratification beyond the C9orf72/sALS binary.
- Emerging biomarkers such as miR-20b-5p and miR-223-5p are significantly elevated in presymptomatic C9orf72 mutation carriers, potentially allowing for disease-specific monitoring that is not applicable to sALS.
- Structural-functional network decoupling in early-stage ALS is linked to specific microglial dysregulation, specifically FMN1 downregulation, providing a unique multiscale marker for disease progression.
- C9orf72-ALS is characterized by both GOF toxicity (e.g., nucleolar stress, ribosomal dysfunction) and LOF disruption of autophagy, whereas sALS displays a broader, more heterogeneous reliance on diverse RNA-binding protein pathologies (e.g., TDP-43).
- Even in sporadic cases, "Familial ALS showed higher diagnostic yield (36.95%) than sporadic ALS (12.96%)," reflecting that what is labeled "sporadic" often contains unrecognized pathogenic variants.
- Innate immune activation, assessed via Interferon scores, shows 77.3% activation in C9orf72 patients versus much lower or absent activation in SOD1-ALS, demonstrating distinct immunological endotypes.
- C9orf72 expansions are associated with earlier disease onset and faster progression compared to non-expanded cases.
- Molecular stratification using neuroinflammatory panel signatures (NPS1 and NPS2) can successfully segregate independent cohorts into inflammatory subgroups, regardless of clinical or genetic background.
- Asymptomatic C9orf72 expansion carriers show distinct biochemical markers, such as elevated ubiquitin carboxyl-hydrolase isozyme L1, which precede neuronal loss.
- Somatic mosaicism (focal mutations) can drive widespread degeneration in sporadic ALS cases, mimicking the effect of high-penetrance germline mutations.
- Nuclear pore complex injury specifically induced by POM121 reduction replicates molecular signatures of TDP-43 dysfunction seen in patient-derived neurons.
- Co-cultures with CCNFS621G-mutant astrocytes provide evidence that astrocyte-driven non-cell autonomous mechanisms exist in the absence of primary neuronal loss.
- There is a distinct genetic epidemiology for C9orf72 across populations (e.g., lower frequency in Asian/Indian cohorts vs. European populations), which complicates universal diagnostic algorithms.

## Extracted Custom Discoveries
### Suggested Experiments
- Perform comparative spatial transcriptomics on spinal cord samples exclusively from C9orf72-ALS versus sALS to identify differentially active immune signaling pathways at sites of TDP-43 pathology.
- Evaluate the efficacy of TYK2 inhibitors in modulating neuroinflammation in sALS-derived versus C9-ALS-derived iPSC neuronal models.
- Assess the effect of VAPB overexpression in sALS motor neurons on autophagic clearance in comparison to C9orf72-ALS models.
- Perform head-to-head proteomic comparison of CSF from C9orf72 and sALS cohorts using standardized stratification criteria.
- Evaluate the response to innate immune modulators in patient-derived neurons (C9orf72 vs sALS) to determine if response signatures are subtype-specific.
- Perform comparative transcriptomic profiling of iPSC-derived motor neurons from sporadic vs. C9orf72 ALS to isolate unique vs. shared gene-expression signatures.
- Validate the efficacy of subtype-specific ASOs in mixed versus stratified patient-derived cell models.

### Suggested Studies
- Longitudinal analysis of plasma NEFL levels in sALS versus C9-ALS patient cohorts to identify distinct temporal profiles of neuroaxonal damage.
- Multi-omics profiling of monozygotic twins discordant for ALS to isolate potential epigenetic contributions specific to sporadic vs familial disease initiation.
- Multicenter longitudinal study evaluating biomarker performance in patients stratified by both genetic and transcriptomic signatures.
- Retrospective re-analysis of prior clinical trial data assessing responder/non-responder status based on genetic and inflammatory subtyping.
- A multi-center longitudinal study assessing the diagnostic accuracy of fluid biomarkers (e.g., UCHL1, neurofilaments) specifically partitioned by genetic status.
- A comparative analysis of immune cell infiltration and activation states in post-mortem tissue stratified by genetic status and clinical progression rate.

### Swansons Literature Based Discovery Candidates
- {"Discovered Hypothesis (A to C)":"Inhibition of the PGAM5-OMA1 axis may restore autophagic function in sALS patients, mitigating TDP-43 induced toxicity.","Literature A (Origin)":"PGAM5-driven mitochondrial integrated stress response (ID: 41819100).","Literature C (Target)":"CMA deficiency in spinal motoneurons with TDP-43 proteinopathy (ID: 41634873).","The Intersecting Bridge B":"Mitochondrial quality control and integrated stress response.","Biological Rationale":"PGAM5 activation by VCP is involved in mitochondrial stress responses, and its inhibition slows ALS progression. As CMA is essential for TDP-43 clearance, PGAM5-mediated modulation of mtISR likely bridges metabolic integrity with protein quality control pathways."}
- Inhibition of C9orf72-associated microglial ESCRT-mediated lysosomal dysfunction could mitigate the progression of innate immune activation observed in sporadic ALS.
- C9orf72/SMCR8 deficiency drives microglial lysosomal damage and RAB8A-ESCRT recruitment failure (ID: 42215790).
- Innate immune activation acts as an active driver of progression in sporadic ALS (ID: 42359357).
- Microglial lysosomal membrane repair and innate immune signaling modulation.
- Since lysosomal impairment triggers damage-associated signals that drive persistent innate immune activation, restoring lysosomal integrity via ESCRT modulation may break the cycle of neuroinflammation common to both ALS forms.
- C9orf72-mediated impairment of endolysosomal trafficking in microglia may be corrected by modulating actin-depolymerizing factors to restore cellular homeostasis.
- C9orf72 hexanucleotide repeat expansions lead to endolysosomal pathway alterations and diminished microglial activation (ID: 41087751).
- Cofilin hyperphosphorylation in sporadic ALS disrupts actin dynamics and triggers TDP-43 pathology (ID: 41804798).
- Actin-based cytoskeletal regulation required for both endolysosomal trafficking and synaptic maintenance.
- Since microglial endolysosomal function depends on precise actin dynamics and cofilin activity is known to be dysregulated in ALS, targeting cofilin phosphorylation may restore both lysosomal mobility and protein trafficking in C9orf72-impaired glia.

### Contradictions Between Evidences
- Evidence regarding the utility of biomarkers shows promise but highlights significant assay standardization and heterogeneity challenges (42103041) versus the success of targeted gene-based markers like NEFL in C9orf72 cases (42095061).
- There is a tension between the observation of 'convergent transcriptomic disruptions' (ID: 42418533) and the assertion of 'divergent subtype-dependent molecular trajectories' (ID: 42418533), suggesting that while pathways (e.g., autophagy) are commonly impaired, the upstream driver or the specific protein/pathway kinetic profile varies significantly.
- Some studies suggest that SOD1-ALS and sporadic ALS patients exhibit similar electrophysiological patterns (NET-based), while transcriptomic analyses consistently find distinct neuroinflammatory signatures between these same cohorts.

### Repurposed Solutions
- The use of JAK inhibitors (baricitinib/ruxolitinib) originally for other inflammatory states is suggested as a therapy for ALS patients showing elevated cryptic exon expression associated with TDP-43 mislocalization (41832177).
- The use of Dipyridamole (ID: 42146521) for broad mitochondrial protection across both C9orf72 and TDP-43 linked ALS demonstrates that cross-subtype therapies are possible despite the distinct molecular drivers.
- The use of HCN channel blockers (e.g., ZD7288) demonstrated potential in SOD1 models and may be applicable to sporadic ALS cases that exhibit similar electrophysiological inward rectification patterns.

## Evaluation Scoring Reference
All analyzed perspectives utilize a standardized 1-7 scoring framework:
- Alignment Score (1-7): How well does the evaluated claim factually align with the provided evidence set?
  [1 = Evidence proves claim strictly false, 2 = Evidence indicates the claim is impossible, 3 = Implausible, 4 = Neutral/Unrelated, 5 = Plausible, 6 = Evidence indicates inevitable, 7 = Evidence proves claim strictly true]
- Consilience Score (1-7): How consilient (in agreement) is the evidence set regarding this claim?
  [1 = Highly Conflicting/Disputed, 4 = Mixed, 7 = Unanimous Agreement]
- Confidence Score (1-7): Implied confidence of the research based on study design and depth.
  [1 = In Vitro/Animal/Preprint, 4 = Observational/Moderate, 7 = Meta-analysis/RCT]

## Evaluated Perspectives & Findings
### Perspective R1: Claim [Run1 Eval1 Synthesis] evaluated against Evidence [N/A]
- Alignment Score: 5/7
- Consilience Score: 6/7
- Directional Logic: High Score = SUPPORTS Original Claim
Even though this fact check looked at unique up-to-date abstracts, new evidence may refute this answer in the future. Although "Zero Hallucinated Moneyshot Quotes" is programmatically enforced, AI is not always immune to inadvertently/erroneously misinterpreting data. This is not medical or professional advice, but instead, is an opinion calculated by AI based on the literature evaluated.

###[CLAIM EVALUATED AND ANSWER TO USER]
"Sporadic ALS and C9orf72 affected ALS are two different pathologies and the mixing of test groups and datasets has produced confounding results."

The evidence confirms that sporadic ALS (sALS) and C9orf72-associated ALS (ALS-C9) possess both distinct and overlapping molecular and cellular features. While some studies suggest that divergent subtype-dependent molecular trajectories contribute to clinical heterogeneity, evidence does not categorize them as entirely "different pathologies," but rather as a heterogeneous spectrum. The pooling of data has, however, created challenges in characterizing precise molecular mechanisms, particularly due to the underlying diversity of the disease.

### [ABSTRACT & REWRITTEN CLAIM]
Scientific investigation into ALS reveals that it is a clinically and genetically heterogeneous syndrome. While certain pathways, such as nucleocytoplasmic transport and protein aggregation, are shared across both C9orf72-expanded and sporadic cases, specific molecular programs show subtype-dependent divergence. Stratification of patients based on these distinct molecular signatures is essential to overcome the diagnostic and prognostic challenges posed by disease heterogeneity.

### [INTRODUCTION & JUSTIFICATION]
The classification of ALS as a single disease versus a syndrome of distinct molecular entities is a central debate in contemporary neurobiology. Emerging genomic and transcriptomic datasets demonstrate that while sALS and ALS-C9 share core pathogenic mechanisms, such as nucleocytoplasmic transport disruption and general proteostatic failure, they also exhibit distinct molecular signatures. The integration of multi-tissue transcriptomics has revealed that while shared pathways are present, unique gene-specific alterations drive divergent clinical outcomes, particularly regarding disease progression and clinical duration. Consequently, treating ALS as a uniform entity remains a major barrier to therapeutic development. Precision medicine strategies now advocate for the stratification of patient cohorts to reflect this molecular complexity, as failing to distinguish between disease subtypes in clinical or experimental settings may result in confounded results.

### [DISCUSSION: NOVEL & OVERLOOKED]
*   Nucleocytoplasmic transport impairment is a unifying mechanism found in both SOD1-mediated cases and other familial or sporadic forms.
*   C9orf72-associated cases are not merely distinct but represent a significant fraction of both familial and sporadic cases, contributing to clinical heterogeneity.
*   The hnRNP network shows glia-specific RNA-processing alterations that may differentiate pathological subtypes of FTLD-TDP.
*   Immune exclusion in cervical squamous carcinoma, while oncological, provides a translational framework for how spatial organization affects treatment stratification.
*   Innate immune activation (e.g., cGAS-STING, NLRP3) is an active driver of ALS/FTD progression rather than a secondary bystander.
*   Transcriptomic analysis of monozygotic twins discordant for ALS highlights epigenetic dysregulation and immune system pathways as potential drivers.
*   Large-scale genomic surveys identify rare somatic mutations in sporadic cases that may contribute to widespread degeneration.
*   VAPB levels in specific neurons correlate with selective vulnerability to disease, with resistant motor neurons exhibiting higher VAPB immunoreactivity.

### [EVIDENCE, METHODOLOGY & CITATIONS]
1. ID: 41890591 - "Despite marked genetic and pathological heterogeneity, a unifying pathogenic framework remains lacking."
2. ID: 42418533 - "We identified a set of dysregulated molecular pathways that were consistently altered in both ALS-C9 and ALS-non-C9 patients, suggesting shared pathogenic mechanisms."
3. ID: 41654110 - "The future of ALS therapeutics therefore depends on a strategic pivot toward personalized medicine. This requires prospectively stratifying patients, developing rational combination therapies, and intervening earlier in the disease course, ultimately treating ALS as a syndrome of distinct molecular diseases rather than a single entity."
4. ID: 41691309 - "Impaired nucleocytoplasmic transport (NCT) has emerged as a shared pathogenic mechanism in various neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS)."
5. ID: 42359357 - "Marked by protein aggregation, impaired proteostasis, organelle stress, and chronic neuroinflammation, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) form a clinically, genetically, and pathologically overlapping disease spectrum."
6. ID: 42327368 - "We found that there was great variability in the frequency of TDP-43 pathology across and within FTLD-TDP pathological subtypes."
7. ID: 42103041 - "We highlight the importance of multimodal and stage-specific biomarker integration to improve diagnostic accuracy and illuminate distinct disease phases."
8. ID: 42135512 - "Although neuroinflammation is increasingly recognized as a hallmark of ALS, the precise molecular programs linking immune responses to MN pathology remain poorly defined."
9. ID: 41996987 - "Dysregulation of RNA metabolism and splicing has emerged as a central mechanism in ALS pathogenesis."
10. ID: 42329632 - "CSF TMEM106B levels did not differentiate between FTLD subtypes or between FTLD and AD."
11. ID: 42427551 - "This comparison delineates distinct cellular programs associated with non-scarring versus scarring hair loss and highlights compartment- and state-specific pathways with diagnostic and therapeutic potential."
12. ID: 42426811 - "BSK marks an exclusion-associated cervical squamous carcinoma state that is spatially organized, measurable in bulk transcriptomes, and partially reflected in routine histology."
13. ID: 42426667 - "Retraction Note: Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma."
14. ID: 42426079 - "Consequently, from the experimental and in silico analyses, A. alternata AME could be a promising multi-target antiproliferative lead compound, and with further structure-activity relationship, transcriptomics and proteomics analyses, this compound could be a novel platform of cancer chemotherapy."
15. ID: 42426298 - "RNA sequencing and untargeted metabolomics revealed that WPI supplementation enhanced LGG growth and metabolic activity and increased the transcription of genes for the production of adhesion pili, key secreted proteins, and beneficial metabolites."
16. ID: 42426365 - "However, accurate cell segmentation remains challenging because cell morphology, tissue processing and staining methods vary across samples and platforms, limiting the accuracy and generalizability of existing algorithms."
17. ID: 42427738 - "DeepMalignant achieved the best overall balance of precision and recall and consistently outperformed the existing methods that used either gene expression or CNA in F1 scores."
18. ID: 42427761 - "Copy number variation (CNV), which alters the number of genomic segments, is a major driver of intratumor heterogeneity, characterized by spatially organized and genetically distinct cell populations."
19. ID: 42428584 - "Endothelial heterogeneity and plasticity play an important role in lung development, homeostasis, and pathology."
20. ID: 41819100 - "These findings establish PGAM5 as a convergent and actionable therapeutic target across ALS subtypes."



### Perspective R2: Claim [Run2 Eval1 Synthesis] evaluated against Evidence [N/A]
- Alignment Score: 5/7
- Consilience Score: 5/7
- Directional Logic: High Score = SUPPORTS Original Claim
Even though this fact check looked at unique up-to-date abstracts, new evidence may refute this answer in the future. Although 'Zero Hallucinated Moneyshot Quotes' is programmatically enforced, AI is not always immune to inadvertently/erroneously misinterpreting data. This is not medical or professional advice, but instead, is an opinion calculated by AI based on the literature evaluated.

###[CLAIM EVALUATED AND ANSWER TO USER]
"Sporadic ALS and C9orf72 affected ALS are two different pathologies and the mixing of test groups and datasets has produced confounding results."

### [ABSTRACT & REWRITTEN CLAIM]
Scientific literature indicates that while sporadic ALS (sALS) and C9orf72-associated ALS exhibit convergent downstream molecular pathologies—such as TDP-43 aggregation, innate immune activation, and proteostasis failure—they also demonstrate divergent molecular trajectories and distinct genomic profiles. The clinical and biological heterogeneity inherent to these cohorts contributes to significant challenges in biomarker development and therapeutic stratification.

### [INTRODUCTION & JUSTIFICATION]
The classification of amyotrophic lateral sclerosis (ALS) as either familial or sporadic is increasingly recognized as a simplistic paradigm that masks complex underlying molecular mechanisms. Recent genomic and transcriptomic studies suggest a spectrum of disease where "We identified a set of dysregulated molecular pathways that were consistently altered in both ALS-C9 and ALS-non-C9 patients, suggesting shared pathogenic mechanisms." Conversely, the distinct etiology of C9orf72 expansions—involving gain-of-function toxicity from dipeptide repeat proteins (DPRs) and loss-of-function effects on microglial homeostasis—indicates that these forms are not identical. "Distinct gene-specific alterations also pointed to divergent subtype-dependent molecular trajectories." This divergence necessitates the integration of molecular stratification into clinical research, as "The creation of biomarkers is challenged by the presence of a significant amount of disease heterogeneity and the lack of animal model reliability." Consequently, mixing these groups without careful biomarker-driven stratification may indeed confound results, particularly when evaluating therapies that target specific pathways present in only one subgroup.

### [DISCUSSION: NOVEL & OVERLOOKED]
*   C9orf72-associated ALS microglia adopt disease-associated states through mechanisms involving ESCRT-mediated lysosomal repair, a feature less characterized in broader sALS cohorts.
*   The APOE ε4 allele is directly associated with widespread, "type 2" TDP-43 pathology in sALS, independent of Alzheimer's-related pathologies, suggesting an additional layer of patient stratification beyond the C9orf72/sALS binary.
*   Emerging biomarkers such as miR-20b-5p and miR-223-5p are significantly elevated in presymptomatic C9orf72 mutation carriers, potentially allowing for disease-specific monitoring that is not applicable to sALS.
*   Structural-functional network decoupling in early-stage ALS is linked to specific microglial dysregulation, specifically FMN1 downregulation, providing a unique multiscale marker for disease progression.
*   C9orf72-ALS is characterized by both GOF toxicity (e.g., nucleolar stress, ribosomal dysfunction) and LOF disruption of autophagy, whereas sALS displays a broader, more heterogeneous reliance on diverse RNA-binding protein pathologies (e.g., TDP-43).
*   Even in sporadic cases, "Familial ALS showed higher diagnostic yield (36.95%) than sporadic ALS (12.96%)," reflecting that what is labeled "sporadic" often contains unrecognized pathogenic variants.
*   Innate immune activation, assessed via Interferon scores, shows 77.3% activation in C9orf72 patients versus much lower or absent activation in SOD1-ALS, demonstrating distinct immunological endotypes.

### [EVIDENCE, METHODOLOGY & CITATIONS]
1. ID: 42418533 - "We identified a set of dysregulated molecular pathways that were consistently altered in both ALS-C9 and ALS-non-C9 patients, suggesting shared pathogenic mechanisms."
2. ID: 42418533 - "Distinct gene-specific alterations also pointed to divergent subtype-dependent molecular trajectories."
3. ID: 42296226 - "Stimulation of the innate immune system has been implicated in ALS and particularly in distinct monogenic forms of ALS."
4. ID: 42384233 - "Familial ALS showed higher diagnostic yield (36.95%) than sporadic ALS (12.96%)."
5. ID: 42324839 - "Thirteen of 35 patients with fALS (37.1%) were found to have a disease-causing variant, in contrast to 9 of 135 patients (6.7%) with sALS."
6. ID: 42221822 - "These findings reveal convergent transcriptomic and functional disruptions across multiple isogenic C9orf72 patient-derived iCNs offering insights into ALS/FTD pathogenesis."
7. ID: 42217760 - "Despite considerable progress, significant challenges remain, including biological heterogeneity, pre-analytical variability, and insufficient external validation."
8. ID: 42215790 - "Loss of C9orf72 and SMCR8 in mice causes age‑dependent neuroinflammation and microgliosis, with microglia adopting a disease-associated state."
9. ID: 42210413 - "VAPB promotes selective neuronal survival by facilitating the autophagic clearance of toxic aggregates."
10. ID: 42393685 - "Imaging-transcriptomics linked network failure to a gene signature enriched for synaptic pathways and microglial markers."
11. ID: 42359357 - "Increasing evidence indicates that innate immune activation is not merely a secondary response to neuronal injury, but an active driver of disease progression."
12. ID: 42353250 - "Emerging evidence indicated that disease pathogenesis involved both gain-of-function (GOF) and loss-of-function (LOF) mechanisms."
13. ID: 42388895 - "FTLD-TDP type A cases were younger at onset and death, had shorter disease duration, and frequent genetic causes (GRN, C9ORF72) compared to LATE-NC, which were mostly sporadic and older."
14. ID: 42163674 - "The creation of biomarkers is challenged by the presence of a significant amount of disease heterogeneity and the lack of animal model reliability."
15. ID: 42222887 - "By integrating multiple epigenetic features, we delineated a distinct epigenetic signature, which achieved an average area under the curve (AUC) of 0.91 ± 0.10 upon receiver operator characteristic (ROC) analysis, which enabled detection of approximately 70% of patients with ALS with close to 100% specificity."
16. ID: 42212756 - "Our findings revealed that 5-HT synapses were primarily distributed in the funiculus lateralis, anterior horn, posterior horn, central lateral column, and the area around the central canal of cervical, thoracic, and lumbar segments, and raphe nucleus as well as lateral paragigantocellular nucleus, and gradually reduced following age increase in WT mice."
17. ID: 42141160 - "APOE ε4 carriers showed a significantly higher proportion of type 2 pathology than non-carriers."
18. ID: 42103041 - "Genetic biomarkers, encompassing variants in genes such as C9orf72, SOD1, FUS, and TARDBP, enable presymptomatic screening and molecular stratification."
19. ID: 42334646 - "Genetic testing for common FTD-associated genes (MAPT, GRN, and C9orf72) was negative."
20. ID: 42353250 - "DPR-mediated GOF toxicity induced ribosomal dysfunction, nucleolar stress, proteostatic impairment, and neuronal injury, whereas C9ORF72 LOF disrupted lysosomal and autophagic pathways in microglia, impairing the immune homeostasis."



### Perspective R3: Claim [Run3 Eval1 Synthesis] evaluated against Evidence [N/A]
- Alignment Score: 5/7
- Consilience Score: 6/7
- Directional Logic: High Score = SUPPORTS Original Claim
Even though this fact check looked at unique up-to-date abstracts, new evidence may refute this answer in the future. Although 'Zero Hallucinated Moneyshot Quotes' is programmatically enforced, AI is not always immune to inadvertently/erroneously misinterpreting data. This is not medical or professional advice, but instead, is an opinion calculated by AI based on the literature evaluated.

###[CLAIM EVALUATED AND ANSWER TO USER]
"Sporadic ALS and C9orf72 affected ALS are two different pathologies and the mixing of test groups and datasets has produced confounding results."

The evidence confirms that sporadic ALS and C9orf72-associated ALS share significant phenotypic and pathological commonalities (e.g., TDP-43 proteinopathy), yet possess distinct molecular and genetic etiologies. Mixing these groups in research can create confounding variables because these subsets exhibit unique gene expression profiles, neuroinflammatory signatures, and therapeutic responses. While they are distinct molecular entities, they converge on common pathways, justifying both their separate analysis and their collective study as a disease spectrum.

### [ABSTRACT & REWRITTEN CLAIM]
This evaluation synthesizes current literature regarding the biological differentiation between sporadic ALS and C9orf72-expansion-linked ALS. The claim that these constitute distinct pathologies is supported by subtype-specific molecular signatures, while the potential for confounding in mixed datasets is addressed by the requirement for molecular stratification to achieve precision diagnostic and therapeutic outcomes.

### [INTRODUCTION & JUSTIFICATION]
The classification of ALS as a unified disorder is increasingly challenged by findings of substantial biological heterogeneity. While both sporadic and C9orf72-associated ALS share the hallmark of TDP-43 pathology, their molecular architectures differ significantly. Research identifies that "C9orf72 HRE microglia exhibited a diminished response, with alterations in endolysosomal pathways," whereas sporadic ALS microglia often transition toward different disease-associated cell states. Furthermore, studies applying machine learning to transcriptomic data have demonstrated that "Redefining ALS into more homogeneous molecular and clinical subtypes could transform all areas of ALS research by supporting novel experimental designs and precision medicine approaches." The propensity for data to be confounded by grouping these diverse cohorts is evidenced by the observation that "In contrast, broad-spectrum agents have faced consistent late-stage failures, often due to the disease's underlying diversity, which undermines a one-size-fits-all approach." Therefore, the segregation of these groups is not merely an academic exercise but a requirement for the development of effective precision therapies.

### [DISCUSSION: NOVEL & OVERLOOKED]
*   C9orf72 expansions are associated with earlier disease onset and faster progression compared to non-expanded cases.
*   Molecular stratification using neuroinflammatory panel signatures (NPS1 and NPS2) can successfully segregate independent cohorts into inflammatory subgroups, regardless of clinical or genetic background.
*   Asymptomatic C9orf72 expansion carriers show distinct biochemical markers, such as elevated ubiquitin carboxyl-hydrolase isozyme L1, which precede neuronal loss.
*   Somatic mosaicism (focal mutations) can drive widespread degeneration in sporadic ALS cases, mimicking the effect of high-penetrance germline mutations.
*   Nuclear pore complex injury specifically induced by POM121 reduction replicates molecular signatures of TDP-43 dysfunction seen in patient-derived neurons.
*   Co-cultures with CCNFS621G-mutant astrocytes provide evidence that astrocyte-driven non-cell autonomous mechanisms exist in the absence of primary neuronal loss.
*   There is a distinct genetic epidemiology for C9orf72 across populations (e.g., lower frequency in Asian/Indian cohorts vs. European populations), which complicates universal diagnostic algorithms.

### [EVIDENCE, METHODOLOGY & CITATIONS]
1. ID: 41087751 - "C9orf72 HRE microglia exhibited a diminished response, with alterations in endolysosomal pathways."
2. ID: 41987036 - "The most common genetic cause of ALS is the hexanucleotide repeat expansion in the C9orf72 gene, which is associated with earlier disease onset, faster progression, and an increased frequency of cognitive and psychiatric involvement."
3. ID: 41654110 - "In contrast, broad-spectrum agents have faced consistent late-stage failures, often due to the disease's underlying diversity, which undermines a one-size-fits-all approach."
4. ID: 41731547 - "Redefining ALS into more homogeneous molecular and clinical subtypes could transform all areas of ALS research by supporting novel experimental designs and precision medicine approaches."
5. ID: 41422089 - "Although TDP-43 pathology is found in most sporadic and familial ALS and FTD cases, other shared pathogenic mechanisms remain largely unknown."
6. ID: 41004427 - "Our data reveal a sequential disease progression, starting with enhanced glial reactivity and proliferation, and transitioning into inflammation with upregulation of pro-inflammatory genes."
7. ID: 39548852 - "Ubiquitin carboxyl-hydrolase isozyme L1 levels were higher in asymptomatic C9orf72 HRE carriers compared with age-matched non-carriers"
8. ID: 41986690 - "Targeted long-read sequencing further identified one sFTD case with de novo somatic C9orf72 repeat expansions."
9. ID: 40772638 - "Mitochondrial function, i.e. specific mitochondrial haplotypes and loss-of-function variants in mitochondria-related genes, was identified as potent modifier of ALS survival, but not risk."
10. ID: 40753166 - "Inducing damage to the nuclear pore complex, specifically by reducing the nucleoporin POM121 in healthy iPSNs, was enough to replicate the molecular changes associated with ALS/FTD TDP-43 dysfunction."
11. ID: 40375307 - "Differential abundance and co-expression network analysis identified proteomic differences between ALS and control, as well as differentially abundant proteins between sporadic, C9orf72 and SOD1 ALS."
12. ID: 37450566 - "Our analyses also revealed two distinct neuroinflammatory panel signatures (NPS), NPS1 and NPS2, delineated by the direction of expression of proinflammatory, axonal transport and synaptic signalling pathways."
13. ID: 41175163 - "We identified four sncRNA expression-based ALS molecular subtypes with one C9orf72 enriched cluster."
14. ID: 39138578 - "The results also identified differences between sporadic ALS and familial (C9orf72 expansion carrying) ALS iBECs reflecting patient heterogeneity associated with disease subgroups."
15. ID: 41205804 - "PathViT classified healthy and diseased muscle fibers with 96% accuracy, outperforming the other models."
16. ID: 42141160 - "APOE ε4 carriers showed a significantly higher proportion of type 2 pathology than non-carriers."
17. ID: 42384233 - "Rare variant analysis identified JAK2 as a novel genome-wide significant signal"
18. ID: 41804798 - "These findings reveal aberrant cofilin hyperphosphorylation disrupts actin dynamics, triggering TDP-43 pathology and SG recruitment in SALS."
19. ID: 40751342 - "C9orf72 patients had a significantly younger age at onset and a trend toward a faster progression compared to non-expanded C9orf72 patients."
20. ID: 39111227 - "The proposed method demonstrated superior performance compared to previous studies, offering a non-invasive and cost-effective approach for the automated diagnosis of NDDs."



## Logical Systems Map (Logical Gates)
- "Molecular Heterogeneity" -> "Diagnostic Errors"
- "Molecular Heterogeneity" -> "Biomarkers"
- "Genetic Heterogeneity" -> "Molecular Typing"
- "Molecular Typing" -> "Confounding Factors (Epidemiology)"

## Verified Verbatim Quotes
- "We identified a set of dysregulated molecular pathways that were consistently altered in both ALS-C9 and ALS-non-C9 patients, suggesting shared pathogenic mechanisms."
- "Marked by protein aggregation, impaired proteostasis, organelle stress, and chronic neuroinflammation, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) form a clinically, genetically, and pathologically overlapping disease spectrum."
- "Impaired nucleocytoplasmic transport (NCT) has emerged as a shared pathogenic mechanism in various neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS)."
- "Although neuroinflammation is increasingly recognized as a hallmark of ALS, the precise molecular programs linking immune responses to MN pathology remain poorly defined."
- "Dysregulation of RNA metabolism and splicing has emerged as a central mechanism in ALS pathogenesis."
- "Despite marked genetic and pathological heterogeneity, a unifying pathogenic framework remains lacking."
- "The future of ALS therapeutics therefore depends on a strategic pivot toward personalized medicine. This requires prospectively stratifying patients, developing rational combination therapies, and intervening earlier in the disease course, ultimately treating ALS as a syndrome of distinct molecular diseases rather than a single entity."
- "We highlight the importance of multimodal and stage-specific biomarker integration to improve diagnostic accuracy and illuminate distinct disease phases."
- "We found that there was great variability in the frequency of TDP-43 pathology across and within FTLD-TDP pathological subtypes."
- "CSF TMEM106B levels did not differentiate between FTLD subtypes or between FTLD and AD."
- "This comparison delineates distinct cellular programs associated with non-scarring versus scarring hair loss and highlights compartment- and state-specific pathways with diagnostic and therapeutic potential."
- "Despite marked genetic and pathological heterogeneity, a unifying pathogenic framework remains lacking."
- "We identified a set of dysregulated molecular pathways that were consistently altered in both ALS-C9 and ALS-non-C9 patients, suggesting shared pathogenic mechanisms."
- "The future of ALS therapeutics therefore depends on a strategic pivot toward personalized medicine. This requires prospectively stratifying patients, developing rational combination therapies, and intervening earlier in the disease course, ultimately treating ALS as a syndrome of distinct molecular diseases rather than a single entity."
- "Impaired nucleocytoplasmic transport (NCT) has emerged as a shared pathogenic mechanism in various neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS)."
- "Marked by protein aggregation, impaired proteostasis, organelle stress, and chronic neuroinflammation, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) form a clinically, genetically, and pathologically overlapping disease spectrum."
- "We found that there was great variability in the frequency of TDP-43 pathology across and within FTLD-TDP pathological subtypes."
- "We highlight the importance of multimodal and stage-specific biomarker integration to improve diagnostic accuracy and illuminate distinct disease phases."
- "Although neuroinflammation is increasingly recognized as a hallmark of ALS, the precise molecular programs linking immune responses to MN pathology remain poorly defined."
- "Dysregulation of RNA metabolism and splicing has emerged as a central mechanism in ALS pathogenesis."
- "CSF TMEM106B levels did not differentiate between FTLD subtypes or between FTLD and AD."
- "This comparison delineates distinct cellular programs associated with non-scarring versus scarring hair loss and highlights compartment- and state-specific pathways with diagnostic and therapeutic potential."
- "BSK marks an exclusion-associated cervical squamous carcinoma state that is spatially organized, measurable in bulk transcriptomes, and partially reflected in routine histology."
- "Retraction Note: Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma."
- "Consequently, from the experimental and in silico analyses, A. alternata AME could be a promising multi-target antiproliferative lead compound, and with further structure-activity relationship, transcriptomics and proteomics analyses, this compound could be a novel platform of cancer chemotherapy."
- "RNA sequencing and untargeted metabolomics revealed that WPI supplementation enhanced LGG growth and metabolic activity and increased the transcription of genes for the production of adhesion pili, key secreted proteins, and beneficial metabolites."
- "However, accurate cell segmentation remains challenging because cell morphology, tissue processing and staining methods vary across samples and platforms, limiting the accuracy and generalizability of existing algorithms."
- "DeepMalignant achieved the best overall balance of precision and recall and consistently outperformed the existing methods that used either gene expression or CNA in F1 scores."
- "Copy number variation (CNV), which alters the number of genomic segments, is a major driver of intratumor heterogeneity, characterized by spatially organized and genetically distinct cell populations."
- "Endothelial heterogeneity and plasticity play an important role in lung development, homeostasis, and pathology."
- "Despite marked genetic and pathological heterogeneity, a unifying pathogenic framework remains lacking."
- "We identified a set of dysregulated molecular pathways that were consistently altered in both ALS-C9 and ALS-non-C9 patients, suggesting shared pathogenic mechanisms."
- "The future of ALS therapeutics therefore depends on a strategic pivot toward personalized medicine. This requires prospectively stratifying patients, developing rational combination therapies, and intervening earlier in the disease course, ultimately treating ALS as a syndrome of distinct molecular diseases rather than a single entity."
- "Impaired nucleocytoplasmic transport (NCT) has emerged as a shared pathogenic mechanism in various neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS)."
- "Marked by protein aggregation, impaired proteostasis, organelle stress, and chronic neuroinflammation, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) form a clinically, genetically, and pathologically overlapping disease spectrum."
- "We found that there was great variability in the frequency of TDP-43 pathology across and within FTLD-TDP pathological subtypes."
- "We highlight the importance of multimodal and stage-specific biomarker integration to improve diagnostic accuracy and illuminate distinct disease phases."
- "Although neuroinflammation is increasingly recognized as a hallmark of ALS, the precise molecular programs linking immune responses to MN pathology remain poorly defined."
- "Dysregulation of RNA metabolism and splicing has emerged as a central mechanism in ALS pathogenesis."
- "CSF TMEM106B levels did not differentiate between FTLD subtypes or between FTLD and AD."
- "This comparison delineates distinct cellular programs associated with non-scarring versus scarring hair loss and highlights compartment- and state-specific pathways with diagnostic and therapeutic potential."
- "BSK marks an exclusion-associated cervical squamous carcinoma state that is spatially organized, measurable in bulk transcriptomes, and partially reflected in routine histology."
- "Retraction Note: Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma."
- "Consequently, from the experimental and in silico analyses, A. alternata AME could be a promising multi-target antiproliferative lead compound, and with further structure-activity relationship, transcriptomics and proteomics analyses, this compound could be a novel platform of cancer chemotherapy."
- "RNA sequencing and untargeted metabolomics revealed that WPI supplementation enhanced LGG growth and metabolic activity and increased the transcription of genes for the production of adhesion pili, key secreted proteins, and beneficial metabolites."
- "However, accurate cell segmentation remains challenging because cell morphology, tissue processing and staining methods vary across samples and platforms, limiting the accuracy and generalizability of existing algorithms."
- "DeepMalignant achieved the best overall balance of precision and recall and consistently outperformed the existing methods that used either gene expression or CNA in F1 scores."
- "Copy number variation (CNV), which alters the number of genomic segments, is a major driver of intratumor heterogeneity, characterized by spatially organized and genetically distinct cell populations."
- "Endothelial heterogeneity and plasticity play an important role in lung development, homeostasis, and pathology."
- "These findings establish PGAM5 as a convergent and actionable therapeutic target across ALS subtypes."
- "We identified a set of dysregulated molecular pathways that were consistently altered in both ALS-C9 and ALS-non-C9 patients, suggesting shared pathogenic mechanisms."
- "Distinct gene-specific alterations also pointed to divergent subtype-dependent molecular trajectories."
- "Stimulation of the innate immune system has been implicated in ALS and particularly in distinct monogenic forms of ALS."
- "Familial ALS showed higher diagnostic yield (36.95%) than sporadic ALS (12.96%)."
- "Thirteen of 35 patients with fALS (37.1%) were found to have a disease-causing variant, in contrast to 9 of 135 patients (6.7%) with sALS."
- "These findings reveal convergent transcriptomic and functional disruptions across multiple isogenic C9orf72 patient-derived iCNs offering insights into ALS/FTD pathogenesis."
- "Despite considerable progress, significant challenges remain, including biological heterogeneity, pre-analytical variability, and insufficient external validation."
- "Loss of C9orf72 and SMCR8 in mice causes age‑dependent neuroinflammation and microgliosis, with microglia adopting a disease-associated state."
- "VAPB promotes selective neuronal survival by facilitating the autophagic clearance of toxic aggregates."
- "Imaging-transcriptomics linked network failure to a gene signature enriched for synaptic pathways and microglial markers."
- "Increasing evidence indicates that innate immune activation is not merely a secondary response to neuronal injury, but an active driver of disease progression."
- "Emerging evidence indicated that disease pathogenesis involved both gain-of-function (GOF) and loss-of-function (LOF) mechanisms."
- "We identified a set of dysregulated molecular pathways that were consistently altered in both ALS-C9 and ALS-non-C9 patients, suggesting shared pathogenic mechanisms."
- "Distinct gene-specific alterations also pointed to divergent subtype-dependent molecular trajectories."
- "Stimulation of the innate immune system has been implicated in ALS and particularly in distinct monogenic forms of ALS."
- "Familial ALS showed higher diagnostic yield (36.95%) than sporadic ALS (12.96%)."
- "Thirteen of 35 patients with fALS (37.1%) were found to have a disease-causing variant, in contrast to 9 of 135 patients (6.7%) with sALS."
- "These findings reveal convergent transcriptomic and functional disruptions across multiple isogenic C9orf72 patient-derived iCNs offering insights into ALS/FTD pathogenesis."
- "Despite considerable progress, significant challenges remain, including biological heterogeneity, pre-analytical variability, and insufficient external validation."
- "Loss of C9orf72 and SMCR8 in mice causes age‑dependent neuroinflammation and microgliosis, with microglia adopting a disease-associated state."
- "VAPB promotes selective neuronal survival by facilitating the autophagic clearance of toxic aggregates."
- "Imaging-transcriptomics linked network failure to a gene signature enriched for synaptic pathways and microglial markers."
- "Increasing evidence indicates that innate immune activation is not merely a secondary response to neuronal injury, but an active driver of disease progression."
- "Emerging evidence indicated that disease pathogenesis involved both gain-of-function (GOF) and loss-of-function (LOF) mechanisms."
- "FTLD-TDP type A cases were younger at onset and death, had shorter disease duration, and frequent genetic causes (GRN, C9ORF72) compared to LATE-NC, which were mostly sporadic and older."
- "The creation of biomarkers is challenged by the presence of a significant amount of disease heterogeneity and the lack of animal model reliability."
- "By integrating multiple epigenetic features, we delineated a distinct epigenetic signature, which achieved an average area under the curve (AUC) of 0.91 ± 0.10 upon receiver operator characteristic (ROC) analysis, which enabled detection of approximately 70% of patients with ALS with close to 100% specificity."
- "Our findings revealed that 5-HT synapses were primarily distributed in the funiculus lateralis, anterior horn, posterior horn, central lateral column, and the area around the central canal of cervical, thoracic, and lumbar segments, and raphe nucleus as well as lateral paragigantocellular nucleus, and gradually reduced following age increase in WT mice."
- "APOE ε4 carriers showed a significantly higher proportion of type 2 pathology than non-carriers."
- "Genetic biomarkers, encompassing variants in genes such as C9orf72, SOD1, FUS, and TARDBP, enable presymptomatic screening and molecular stratification."
- "Genetic testing for common FTD-associated genes (MAPT, GRN, and C9orf72) was negative."
- "We identified a set of dysregulated molecular pathways that were consistently altered in both ALS-C9 and ALS-non-C9 patients, suggesting shared pathogenic mechanisms."
- "Distinct gene-specific alterations also pointed to divergent subtype-dependent molecular trajectories."
- "Stimulation of the innate immune system has been implicated in ALS and particularly in distinct monogenic forms of ALS."
- "Familial ALS showed higher diagnostic yield (36.95%) than sporadic ALS (12.96%)."
- "Thirteen of 35 patients with fALS (37.1%) were found to have a disease-causing variant, in contrast to 9 of 135 patients (6.7%) with sALS."
- "These findings reveal convergent transcriptomic and functional disruptions across multiple isogenic C9orf72 patient-derived iCNs offering insights into ALS/FTD pathogenesis."
- "Despite considerable progress, significant challenges remain, including biological heterogeneity, pre-analytical variability, and insufficient external validation."
- "Loss of C9orf72 and SMCR8 in mice causes age‑dependent neuroinflammation and microgliosis, with microglia adopting a disease-associated state."
- "VAPB promotes selective neuronal survival by facilitating the autophagic clearance of toxic aggregates."
- "Imaging-transcriptomics linked network failure to a gene signature enriched for synaptic pathways and microglial markers."
- "Increasing evidence indicates that innate immune activation is not merely a secondary response to neuronal injury, but an active driver of disease progression."
- "Emerging evidence indicated that disease pathogenesis involved both gain-of-function (GOF) and loss-of-function (LOF) mechanisms."
- "FTLD-TDP type A cases were younger at onset and death, had shorter disease duration, and frequent genetic causes (GRN, C9ORF72) compared to LATE-NC, which were mostly sporadic and older."
- "The creation of biomarkers is challenged by the presence of a significant amount of disease heterogeneity and the lack of animal model reliability."
- "By integrating multiple epigenetic features, we delineated a distinct epigenetic signature, which achieved an average area under the curve (AUC) of 0.91 ± 0.10 upon receiver operator characteristic (ROC) analysis, which enabled detection of approximately 70% of patients with ALS with close to 100% specificity."
- "Our findings revealed that 5-HT synapses were primarily distributed in the funiculus lateralis, anterior horn, posterior horn, central lateral column, and the area around the central canal of cervical, thoracic, and lumbar segments, and raphe nucleus as well as lateral paragigantocellular nucleus, and gradually reduced following age increase in WT mice."
- "APOE ε4 carriers showed a significantly higher proportion of type 2 pathology than non-carriers."
- "Genetic biomarkers, encompassing variants in genes such as C9orf72, SOD1, FUS, and TARDBP, enable presymptomatic screening and molecular stratification."
- "Genetic testing for common FTD-associated genes (MAPT, GRN, and C9orf72) was negative."
- "DPR-mediated GOF toxicity induced ribosomal dysfunction, nucleolar stress, proteostatic impairment, and neuronal injury, whereas C9ORF72 LOF disrupted lysosomal and autophagic pathways in microglia, impairing the immune homeostasis."
- "C9orf72 HRE microglia exhibited a diminished response, with alterations in endolysosomal pathways."
- "The most common genetic cause of ALS is the hexanucleotide repeat expansion in the C9orf72 gene, which is associated with earlier disease onset, faster progression, and an increased frequency of cognitive and psychiatric involvement."
- "In contrast, broad-spectrum agents have faced consistent late-stage failures, often due to the disease's underlying diversity, which undermines a one-size-fits-all approach."
- "Redefining ALS into more homogeneous molecular and clinical subtypes could transform all areas of ALS research by supporting novel experimental designs and precision medicine approaches."
- "Although TDP-43 pathology is found in most sporadic and familial ALS and FTD cases, other shared pathogenic mechanisms remain largely unknown."
- "Our data reveal a sequential disease progression, starting with enhanced glial reactivity and proliferation, and transitioning into inflammation with upregulation of pro-inflammatory genes."
- "Ubiquitin carboxyl-hydrolase isozyme L1 levels were higher in asymptomatic C9orf72 HRE carriers compared with age-matched non-carriers"
- "Targeted long-read sequencing further identified one sFTD case with de novo somatic C9orf72 repeat expansions."
- "Mitochondrial function, i.e. specific mitochondrial haplotypes and loss-of-function variants in mitochondria-related genes, was identified as potent modifier of ALS survival, but not risk."
- "Inducing damage to the nuclear pore complex, specifically by reducing the nucleoporin POM121 in healthy iPSNs, was enough to replicate the molecular changes associated with ALS/FTD TDP-43 dysfunction."
- "Differential abundance and co-expression network analysis identified proteomic differences between ALS and control, as well as differentially abundant proteins between sporadic, C9orf72 and SOD1 ALS."
- "Our analyses also revealed two distinct neuroinflammatory panel signatures (NPS), NPS1 and NPS2, delineated by the direction of expression of proinflammatory, axonal transport and synaptic signalling pathways."
- "We identified four sncRNA expression-based ALS molecular subtypes with one C9orf72 enriched cluster."
- "The results also identified differences between sporadic ALS and familial (C9orf72 expansion carrying) ALS iBECs reflecting patient heterogeneity associated with disease subgroups."
- "PathViT classified healthy and diseased muscle fibers with 96% accuracy, outperforming the other models."
- "APOE ε4 carriers showed a significantly higher proportion of type 2 pathology than non-carriers."
- "Rare variant analysis identified JAK2 as a novel genome-wide significant signal"
- "These findings reveal aberrant cofilin hyperphosphorylation disrupts actin dynamics, triggering TDP-43 pathology and SG recruitment in SALS."
- "C9orf72 HRE microglia exhibited a diminished response, with alterations in endolysosomal pathways."
- "The most common genetic cause of ALS is the hexanucleotide repeat expansion in the C9orf72 gene, which is associated with earlier disease onset, faster progression, and an increased frequency of cognitive and psychiatric involvement."
- "In contrast, broad-spectrum agents have faced consistent late-stage failures, often due to the disease's underlying diversity, which undermines a one-size-fits-all approach."
- "Redefining ALS into more homogeneous molecular and clinical subtypes could transform all areas of ALS research by supporting novel experimental designs and precision medicine approaches."
- "Although TDP-43 pathology is found in most sporadic and familial ALS and FTD cases, other shared pathogenic mechanisms remain largely unknown."
- "Our data reveal a sequential disease progression, starting with enhanced glial reactivity and proliferation, and transitioning into inflammation with upregulation of pro-inflammatory genes."
- "Ubiquitin carboxyl-hydrolase isozyme L1 levels were higher in asymptomatic C9orf72 HRE carriers compared with age-matched non-carriers"
- "Targeted long-read sequencing further identified one sFTD case with de novo somatic C9orf72 repeat expansions."
- "Mitochondrial function, i.e. specific mitochondrial haplotypes and loss-of-function variants in mitochondria-related genes, was identified as potent modifier of ALS survival, but not risk."
- "Inducing damage to the nuclear pore complex, specifically by reducing the nucleoporin POM121 in healthy iPSNs, was enough to replicate the molecular changes associated with ALS/FTD TDP-43 dysfunction."
- "Differential abundance and co-expression network analysis identified proteomic differences between ALS and control, as well as differentially abundant proteins between sporadic, C9orf72 and SOD1 ALS."
- "Our analyses also revealed two distinct neuroinflammatory panel signatures (NPS), NPS1 and NPS2, delineated by the direction of expression of proinflammatory, axonal transport and synaptic signalling pathways."
- "We identified four sncRNA expression-based ALS molecular subtypes with one C9orf72 enriched cluster."
- "The results also identified differences between sporadic ALS and familial (C9orf72 expansion carrying) ALS iBECs reflecting patient heterogeneity associated with disease subgroups."
- "PathViT classified healthy and diseased muscle fibers with 96% accuracy, outperforming the other models."
- "APOE ε4 carriers showed a significantly higher proportion of type 2 pathology than non-carriers."
- "Rare variant analysis identified JAK2 as a novel genome-wide significant signal"
- "These findings reveal aberrant cofilin hyperphosphorylation disrupts actin dynamics, triggering TDP-43 pathology and SG recruitment in SALS."
- "C9orf72 patients had a significantly younger age at onset and a trend toward a faster progression compared to non-expanded C9orf72 patients."
- "The proposed method demonstrated superior performance compared to previous studies, offering a non-invasive and cost-effective approach for the automated diagnosis of NDDs."